Bausch & Lomb Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1992-10-08

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Product Performance of a Daily Disposable Contact Lens

Not Applicable

Completed

Conditions: Myopia
Contact Lenses

Interventions: Device: Bausch & Lomb new daily disposable
Device: Johnson & Johnson Acuvue Moist

First Posted Date: 2010-08-31

Last Posted Date: 2014-01-03

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 102

Registration Number: NCT01192126

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle

Phase 3

Completed

Conditions: Bacterial Conjunctivitis

Interventions: Drug: Vehicle
Drug: Besivance

First Posted Date: 2010-08-05

Last Posted Date: 2013-05-01

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 518

Registration Number: NCT01175590

Locations: 🇺🇸
Bausch & Lomb, Inc., Rochester, New York, United States

Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients

Phase 2

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: bepotastine besilate ophthalmic solution
Drug: placebo comparator ophthalmic solution

First Posted Date: 2010-08-04

Last Posted Date: 2020-09-14

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 245

Registration Number: NCT01174823

Locations: 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States

Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome

Phase 2

Completed

Conditions: Dry Eye Syndrome

Interventions: Drug: 2% BOL-303242-X ophthalmic suspension
Drug: 0.3% BOL-303242-X ophthalmic suspension
Drug: 1% BOL-303242-X ophthalmic suspension
Drug: 2% BOL-303242-X ophthalmic suspension AM
Drug: 2% BOL-303242-X ophthalmic suspension PM

First Posted Date: 2010-07-16

Last Posted Date: 2020-09-25

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 356

Registration Number: NCT01163643

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy Volunteers

Phase 3

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: KetoNaph
Drug: Vehicle

First Posted Date: 2010-07-09

Last Posted Date: 2020-10-05

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 534

Registration Number: NCT01159015

Toric Intraocular Lens Following Cataract Surgery

Not Applicable

Completed

Conditions: Cataract
Astigmatism

Interventions: Device: Toric Accommodating Lens
Device: Accommodating Lens

First Posted Date: 2010-06-09

Last Posted Date: 2014-09-08

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 229

Registration Number: NCT01140477

Locations: 🇺🇸
B&L Surgical, Bridgewater, New Jersey, United States

A Study to Assess the Safety and Efficacy of a Daily Disposable Contact Lens

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: Marketed daily disposable contact lens
Device: Bausch & Lomb contact lens

First Posted Date: 2010-05-26

Last Posted Date: 2013-12-10

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 200

Registration Number: NCT01130974

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

Feasibility of a New Silicone Hydrogel Lens

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: Investigational contact lens
Device: Acuvue Oasys Contact Lens
Device: Air Optix Aqua

First Posted Date: 2010-05-26

Last Posted Date: 2014-04-30

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 120

Registration Number: NCT01131130

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

Evaluation of 3 Intraocular Lenses Following Lens Extraction

Phase 4

Completed

Conditions: Cataract

Interventions: Device: ReSTOR
Device: Tecnis Multifocal IOL
Device: Crystalens AO

First Posted Date: 2010-05-13

Last Posted Date: 2014-03-28

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 78

Registration Number: NCT01122576

Locations: 🇺🇸
Bausch & Lomb, Inc, Aliso Viejo, California, United States

Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Besifloxacin Ophthalmic Suspension 0.6%

First Posted Date: 2010-05-11

Last Posted Date: 2012-08-13

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 120

Registration Number: NCT01120418

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy